严重 COVID-19 和白细胞介素-6 受体拮抗剂托珠单抗：一些值得关注的问题。
Severe COVID-19 and interleukin-6 receptor antagonist tocilizumab: Some notes of concern.
机构信息
Department of Internal Medicine and Infectious Diseases, University General Hospital of Patras, Patra, Greece.
出版信息
Respirology. 2020 Nov;25(11):1209. doi: 10.1111/resp.13939. Epub 2020 Sep 20.
Abstract
See related reply
摘要
见相关回复
相似文献
1
Severe COVID-19 and interleukin-6 receptor antagonist tocilizumab: Some notes of concern.严重 COVID-19 和白细胞介素-6 受体拮抗剂托珠单抗：一些值得关注的问题。
Respirology. 2020 Nov;25(11):1209. doi: 10.1111/resp.13939. Epub 2020 Sep 20.
2
Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.抗白细胞介素药物治疗重症 COVID-19 患者（COV-AID）：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 3;21(1):468. doi: 10.1186/s13063-020-04453-5.
3
Tocilizumab and COVID-19: Timing of Administration and Efficacy.托珠单抗与新型冠状病毒肺炎：给药时机与疗效
Front Pharmacol. 2022 Feb 18;13:825749. doi: 10.3389/fphar.2022.825749. eCollection 2022.
4
Clinical efficacy of tocilizumab treatment in severe and critical COVID-19 patients.托珠单抗治疗重型和危重型新型冠状病毒肺炎患者的临床疗效
World J Clin Cases. 2020 Sep 6;8(17):3763-3773. doi: 10.12998/wjcc.v8.i17.3763.
5
Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.托珠单抗治疗 COVID-19 患者的临床结局：一项个体患者数据系统评价。
J Med Virol. 2020 Nov;92(11):2516-2522. doi: 10.1002/jmv.26038. Epub 2020 Jun 9.
6
Tocilizumab and Thromboembolism in COVID-19: A Retrospective Hospital-Based Cohort Analysis.托珠单抗与新冠病毒病中的血栓栓塞：一项基于医院的回顾性队列分析
Cureus. 2021 May 24;13(5):e15208. doi: 10.7759/cureus.15208.
7
Tocilizumab as a Treatment for 'Cytokine Storm Syndrome' in COVID-19: A Case Report.托珠单抗治疗 COVID-19 中的“细胞因子风暴综合征”：一例报告。
Acta Med Indones. 2021 Apr;53(2):194-201.
8
Effect of Tocilizumab in Hospitalized Patients with Severe COVID-19 Pneumonia: A Case-Control Cohort Study.托珠单抗治疗重症新型冠状病毒肺炎住院患者的疗效：一项病例对照队列研究。
Pharmaceuticals (Basel). 2020 Oct 17;13(10):317. doi: 10.3390/ph13100317.
9
Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial.托珠单抗治疗 COVID-19 的疗效：一项非对照、前瞻性临床试验。
Int Immunopharmacol. 2020 Nov;88:106869. doi: 10.1016/j.intimp.2020.106869. Epub 2020 Aug 4.
10
Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab.早期识别 COVID-19 细胞因子风暴并使用阿那白滞素或托珠单抗治疗。
Int J Infect Dis. 2020 Oct;99:291-297. doi: 10.1016/j.ijid.2020.07.081. Epub 2020 Aug 6.
引用本文的文献
1
A randomised trial of in critically ill patients with COVID-19: ARMY-1.一项针对新冠肺炎危重症患者的随机试验：ARMY-1。
ERJ Open Res. 2021 Apr 12;7(2). doi: 10.1183/23120541.00059-2021. eCollection 2021 Apr.
2
Antibody-Based Immunotherapeutic Strategies for COVID-19.针对新型冠状病毒肺炎的基于抗体的免疫治疗策略
Pathogens. 2020 Nov 5;9(11):917. doi: 10.3390/pathogens9110917.
本文引用的文献
1
Appropriate use of tocilizumab in COVID-19 infection.托珠单抗在 COVID-19 感染中的合理应用。
Int J Infect Dis. 2020 Oct;99:338-343. doi: 10.1016/j.ijid.2020.07.036. Epub 2020 Jul 26.
2
Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients.COVID-19 严重急性呼吸窘迫综合征中静脉注射托珠单抗阻断白细胞介素-6 受体：128 例患者回顾性病例对照生存分析。
J Autoimmun. 2020 Nov;114:102511. doi: 10.1016/j.jaut.2020.102511. Epub 2020 Jul 8.
3
Tocilizumab therapy in individuals with COVID-19 infection and hyperinflammatory state.托珠单抗治疗新型冠状病毒肺炎感染及高炎症状态患者
Respirology. 2020 Oct;25(10):1090-1094. doi: 10.1111/resp.13912. Epub 2020 Jul 21.
4
Tocilizumab (Actemra).托珠单抗（雅美罗）。
Hum Vaccin Immunother. 2017 Sep 2;13(9):1972-1988. doi: 10.1080/21645515.2017.1316909.
Zotero 插件